← SIGA TECHNOLOGIES INC (SIGA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
SIGA TECHNOLOGIES INC (SIGA)
Pharmaceutical Preparations · market cap $228M · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
SIGA Technologies is a New York-based specialty pharmaceutical company with a single commercial product, tecovirimat (TPOXX), approved for smallpox treatment and sold primarily to the U.S. Strategic National Stockpile and allied governments. With $145.6M in cash against a $254M market cap and a 50-month runway, the company is financially stable but revenue is inherently lumpy, dependent on government procurement cycles rather than a traditional commercial market. A Phase 3 program in smallpox and a Phase 2 mpox/smallpox vaccine candidate represent the pipeline, but no near-term binary catalysts are flagged outside a routine earnings report.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| tecovirimat | Phase 3 | Smallpox |
| Smallpox and Mpox Vaccine | Phase 2 | Smallpox |
| ST-246 400 mg | Phase 2 | Orthopoxviral Disease |
| TPOXX | Phase 3 | Smallpox |
Price & technical context
3-month
-13.2%
6-month
-35.2%
12-month
-63.4%
52-wk range
$2.87–$9.23
vs 50-day MA
+6.8%
vs 200-day MA
-29.0%
Realized vol
48.7%
Max drawdown
-69.7%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SIGA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.